 Connection
Elizabeth McFarland to Lamivudine
This is a "connection" page, showing publications Elizabeth McFarland has written about Lamivudine.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.102 |
|
|
|
-
Melvin AJ, Yee KL, Gray KP, Yedla M, Wan H, Tobin NH, Teppler H, Campbell H, McCarthy K, Scheckter R, Aurpibul L, Ounchanum P, Rungmaitree S, Cassim H, McFarland E, Flynn P, Cooper E, Krotje C, Townley E, Moye J, Best BM. Pharmacokinetics, Tolerability, and Safety of Doravirine and Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate Fixed-Dose Combination Tablets in Adolescents Living With HIV: Week 24 Results From IMPAACT 2014. J Acquir Immune Defic Syndr. 2023 02 01; 92(2):153-161.
Score: 0.052
-
Smith C, Forster JE, Levin MJ, Davies J, Pappas J, Kinzie K, Barr E, Paul S, McFarland EJ, Weinberg A. Serious adverse events are uncommon with combination neonatal antiretroviral prophylaxis: a retrospective case review. PLoS One. 2015; 10(5):e0127062.
Score: 0.030
-
Weinberg A, Forster-Harwood J, McFarland EJ, Pappas J, Davies JK, Kinzie K, Barr EA, Paul SM, Salbenblatt CR, Soda E, Vazquez A, Levin MJ. Resistance to antiretrovirals in HIV-infected pregnant women. J Clin Virol. 2009 May; 45(1):39-42.
Score: 0.020
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|